PDCD1 and neoplasm: showed that targeting Annexin A1 downregulated CD25, C-C chemokine receptor 8 (CXCR8), and programmed cell death protein 1 (PD-1) expression and reduced the function of Treg cells, thereby enhancing anti-tumor immunity in TNBC (25).